Qube Research & Technologies (QRT)’s AbbVie ABBV Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$60.3M	Sell	277,200 -138,200	-33%	-$30.7M	0.07%	363
2025 Q4	$94.9M	Buy	415,400 +5,000	+1%	+$1.14M	0.1%	262
2025 Q3	$95M	Sell	410,400 -118,800	-22%	-$24.2M	0.1%	249
2025 Q2	$98.2M	Buy	529,200 +150,500	+40%	+$28M	0.1%	260
2025 Q1	$79.3M	Buy	378,700 +183,500	+94%	+$35.7M	0.09%	274
2024 Q4	$34.7M	Sell	195,200 -1,800	-0.9%	-$331K	0.05%	503
2024 Q3	$38.9M	Sell	197,000 -42,900	-18%	-$8.01M	0.06%	418
2024 Q2	$41.1M	Buy	239,900 +3,200	+1%	+$530K	0.07%	350
2024 Q1	$43.1M	Buy	236,700 +162,600	+219%	+$28M	0.07%	338
2023 Q4	$11.5M	Buy	+74,100	New	+$10.8M	0.02%	688
2023 Q2	–	Sell	-50,000	Closed	-$7.97M	–	2334
2023 Q1	$7.97M	Buy	50,000 +25,000	+100%	+$3.82M	0.03%	537
2022 Q4	$4.04M	Buy	+25,000	New	+$3.83M	0.02%	720
2022 Q3	–	Sell	-25,000	Closed	-$3.83M	–	2455
2022 Q2	$3.83M	Hold	25,000	–	–	0.03%	582
2022 Q1	$4.05M	Buy	+25,000	New	+$3.63M	0.03%	568

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ABBV Position: Q1 2026 in Review

Qube Research & Technologies (QRT) sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 1,093,561 shares — an estimated $243M sold.

Qube Research & Technologies (QRT) first reported a position in ABBV in Q1 2018 and held it in 25 quarters. The position peaked at $634M in Q2 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Qube Research & Technologies (QRT) reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
Qube Research & Technologies (QRT) sold 1,093,561 AbbVie shares in Q1 2026, an estimated $243M.
Qube Research & Technologies (QRT) first reported a position in AbbVie in Q1 2018 and held it in 25 quarters.
Qube Research & Technologies (QRT)'s AbbVie position peaked at $634M in Q2 2025.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.